Neupulse Secures £500,000 Funding for Tourette's Device
Neupulse, an innovative spinout from the University of Nottingham in the UK, has successfully secured an impressive £500,000 in equity funding to bolster its operations and advance its groundbreaking medical technology. This critical funding was raised through the Midlands Engine Investment Fund II, which was facilitated by Mercia Ventures, the appointed fund manager for the East and South East Midlands. This recent funding comes on the heels of a substantial £2.5 million investment obtained earlier in the year from a consortium that included Eos Advisory as well as investors based in the United States. With this latest investment, Neupulse's total fundraising efforts have now reached nearly £4.5 million, indicating strong investor confidence in the company's pioneering approach.
The primary aim of this newly acquired funding is to finalize the development of Neupulse's innovative wristband device, which is designed to manage symptoms of Tourette’s syndrome effectively.
The company is strategically planning to carry out further clinical trials and is actively seeking regulatory approvals in key markets including the UK, Europe, and the USA. By enhancing their device through continued research and testing, Neupulse hopes to establish its technology as a viable, non-pharmaceutical treatment option for individuals who struggle with the challenges posed by Tourette’s syndrome, enhancing their quality of life significantly.
Founded in 2021 by the accomplished team of Professors Stephen and Georgina Jackson, alongside Dr. Barbara Morera at the University of Nottingham, Neupulse is headed by its CEO, Paul Cable. The company's device offers a safe method of treatment that utilizes electrical stimulation of the median nerve located in the wrist, aiming to control the involuntary movements and tics associated with Tourette’s syndrome. Initial clinical trials have shown promising results, indicating that the device can achieve an average reduction of tic frequency by approximately 25% after just the first use. Moreover, users have reported an even greater alleviation of symptoms after four weeks of consistent use, marking Neupulse as a front-runner in developing non-drug therapies for this challenging condition.
They've invested in Neupulse
Get to know these Healthtech investors
Click here for a full list of 7,526+ startup investors in the UK